NCT04542135View on ClinicalTrials.gov

Sulindac and Breast Density in Women at Risk of Developing Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

April 22, 2025

Study Completion Date

May 19, 2025

Conditions
Breast Cancer
Interventions
DRUG

Sulindac Pill

Randomized participants will receive either 150 mg oral sulindac twice daily.

DRUG

Placebo

placebo pills twice daily

Trial Locations (2)

11794

Stony Brook University Cancer Center, Stony Brook

90048

Cedars Sinai - Cancer, Los Angeles

All Listed Sponsors
collaborator

Medical University of South Carolina

OTHER

collaborator

Cedars-Sinai Medical Center

OTHER

lead

Alison Stopeck

OTHER

NCT04542135 - Sulindac and Breast Density in Women at Risk of Developing Breast Cancer | Biotech Hunter | Biotech Hunter